Roxadustat
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Roxadustat (FibroGen/Astellas/AstraZeneca) is a hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitor in development for the treatment of anemia in chronic kidney disease. The drug is administered orally three times per week and mimics the body’s natural response to reduced oxygen levels by increasing levels of HIFs. These factors are involved in erythropoiesis. Roxadustat treats anemia primarily by reducing hepcidin levels, increasing iron transport and absorption proteins, and stimulating erythropoietin production.
TABLE OF CONTENTS
4 Product Profiles
4 roxadustat : Anemia in chronic kidney disease
LIST OF FIGURES
10 Figure 1: Roxadustat for anemia in chronic kidney disease – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of roxadustat for anemia in chronic kidney disease
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of roxadustat for anemia in chronic kidney disease
14 Figure 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
LIST OF TABLES
5 Table 1: Roxadustat drug profile
6 Table 2: Roxadustat Phase III trials in anemia in chronic kidney disease
8 Table 3: Roxadustat Phase II and III data in anemia in chronic kidney disease
15 Table 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Venofer 
Sign up to the